Actavia Life Sciences, Inc. (RASP)
Actavia Life Sciences, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in New York City, NY, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $385,906. On trailing twelve-month figures it carries a trailing P/E of -0.06, a net margin of 0.0%. Its beta of -6.97 implies it has historically moved less than the broad market.
Actavia Life Sciences, Inc. operates as a biotechnology enterprise specializing in the development of therapeutic solutions aimed at treating various forms of leukemia and lymphoma. Additionally, the company is engaged in formulating small molecule drug candidates, with a particular emphasis on addressing acute myeloid leukemia. Established in 2013, its corporate headquarters are situated in New York, NY.
Actavia Life Sciences, Inc. is most often compared with the following Healthcare names: